These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

808 related articles for article (PubMed ID: 18976723)

  • 1. Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity.
    Maru BS; Tobias JH; Rivers C; Caunt CJ; Norman MR; McArdle CA
    Bone; 2009 Jan; 44(1):102-12. PubMed ID: 18976723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for estrogenicity and anti-estrogenicity: a critical evaluation of an MVLN cell-based transactivation assay.
    Freyberger A; Schmuck G
    Toxicol Lett; 2005 Jan; 155(1):1-13. PubMed ID: 15585354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional regulation of a BMP-6 promoter by estrogen receptor alpha.
    Ong DB; Colley SM; Norman MR; Kitazawa S; Tobias JH
    J Bone Miner Res; 2004 Mar; 19(3):447-54. PubMed ID: 15040833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells.
    Gougelet A; Bouclier C; Marsaud V; Maillard S; Mueller SO; Korach KS; Renoir JM
    J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):71-81. PubMed ID: 15862952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA; Oza BP; Colomer R; Lupu R
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta.
    Escande A; Pillon A; Servant N; Cravedi JP; Larrea F; Muhn P; Nicolas JC; Cavaillès V; Balaguer P
    Biochem Pharmacol; 2006 May; 71(10):1459-69. PubMed ID: 16554039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor.
    Levenson AS; Svoboda KM; Pease KM; Kaiser SA; Chen B; Simons LA; Jovanovic BD; Dyck PA; Jordan VC
    Cancer Res; 2002 Aug; 62(15):4419-26. PubMed ID: 12154049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
    Lewis JS; Jordan VC
    Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A trans-acting enhancer modulates estrogen-mediated transcription of reporter genes in osteoblasts.
    Sasaki-Iwaoka H; Maruyama K; Endoh H; Komori T; Kato S; Kawashima H
    J Bone Miner Res; 1999 Feb; 14(2):248-55. PubMed ID: 9933479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, structure, and estrogenic activity of 4-amino-3-(2-methylbenzyl)coumarins on human breast carcinoma cells.
    Jacquot Y; Laïos I; Cleeren A; Nonclercq D; Bermont L; Refouvelet B; Boubekeur K; Xicluna A; Leclercq G; Laurent G
    Bioorg Med Chem; 2007 Mar; 15(6):2269-82. PubMed ID: 17275315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a stable dual cell-line GFP expression system to study estrogenic endocrine disruptors.
    Xu H; Kraus WL; Shuler ML
    Biotechnol Bioeng; 2008 Dec; 101(6):1276-87. PubMed ID: 18980187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prenylation inhibitors stimulate both estrogen receptor alpha transcriptional activity through AF-1 and AF-2 and estrogen receptor beta transcriptional activity.
    Cestac P; Sarrabayrouse G; Médale-Giamarchi C; Rochaix P; Balaguer P; Favre G; Faye JC; Doisneau-Sixou S
    Breast Cancer Res; 2005; 7(1):R60-70. PubMed ID: 15642170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of selective estrogen receptor modulator (SERM) action.
    Dutertre M; Smith CL
    J Pharmacol Exp Ther; 2000 Nov; 295(2):431-7. PubMed ID: 11046073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of estrogenic/antiestrogenic activity of Onobrychis ebenoides extract - interaction with estrogen receptor subtypes ERalpha and ERbeta.
    Papoutsi Z; Kassi E; Halabalaki M; Mitakou S; Moutsatsou P
    Toxicol In Vitro; 2007 Apr; 21(3):364-70. PubMed ID: 17092687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A HOXA10 estrogen response element (ERE) is differentially regulated by 17 beta-estradiol and diethylstilbestrol (DES).
    Akbas GE; Song J; Taylor HS
    J Mol Biol; 2004 Jul; 340(5):1013-23. PubMed ID: 15236964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of human estrogen receptor alpha F promoter by a protein kinase C/c-Src-dependent mechanism in osteoblast-like cells.
    Longo M; Peruzzi B; Fortunati D; De Luca V; Denger S; Caselli G; Migliaccio S; Teti A
    J Mol Endocrinol; 2006 Dec; 37(3):489-502. PubMed ID: 17170089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of environmental estrogenic chemicals on AP1 mediated transcription with estrogen receptors alpha and beta.
    Fujimoto N; Kitamura S
    J Steroid Biochem Mol Biol; 2004 Jan; 88(1):53-9. PubMed ID: 15026083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raloxifene induces nucleolar translocation of the estrogen receptor.
    Gushima M; Kawate H; Ohnaka K; Nomura M; Takayanagi R
    Mol Cell Endocrinol; 2010 May; 319(1-2):14-22. PubMed ID: 20083158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen agonism and estrogen antagonism of c-fos gene promoter activity through non-consensus-responsive elements in MC3T3-E1 osteoblasts.
    Ishibashi O; Yamagishi T; Hanada K; Kawashima H
    Biochem Biophys Res Commun; 2001 Dec; 289(3):705-11. PubMed ID: 11726205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptors: selective ligands, partners, and distinctive pharmacology.
    Katzenellenbogen BS; Montano MM; Ediger TR; Sun J; Ekena K; Lazennec G; Martini PG; McInerney EM; Delage-Mourroux R; Weis K; Katzenellenbogen JA
    Recent Prog Horm Res; 2000; 55():163-93; discussion 194-5. PubMed ID: 11036937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.